Details

Autor(en) / Beteiligte

• Lutrick, Karen
• Rivers, Patrick
• Yoo, Young M
• Grant, Lauren
• Hollister, James
• Jovel, Krystal
• Khan, Sana
• Lowe, Ashley
• Baccam, Zoe
• Hanson, Hanna
• Olsho, Lauren E W
• Fowlkes, Ashley
• Caban-Martinez, Alberto J
• Porter, Cynthia
• Yoon, Sarang
• Meece, Jennifer
• Gaglani, Manjusha
• Burns, Joy
• Mayo Lamberte, Julie
• Nakayima Miiro, Flavia
• Bissonnette, Adam
• LeClair, Lindsay
• Kutty, Preeta K
• Romine, James K
• Stefanski, Elisha
• Edwards, Laura J
• Ellingson, Katherine
• Gerald, Joe K
• Bedrick, Edward J
• Madhivanan, Purnima
• Krupp, Karl
• Gerald, Lynn B
• Thompson, Mark
• Burgess, Jefferey L

Titel

Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021

Ist Teil von

• MMWR. Morbidity and mortality weekly report, 2021-12, Vol.70 (5152), p.1761-1765

Ort / Verlag

United States: U.S. Government Printing Office

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine has demonstrated high efficacy in preventing infection with SARS-CoV-2 (the virus that causes COVID-19) in randomized placebo-controlled Phase III trials in persons aged 12-17 years (referred to as adolescents in this report) (1); however, data on real-word vaccine effectiveness (VE) among adolescents are limited (1-3). As of December 2021, the Pfizer-BioNTech vaccine is approved by the Food and Drug Administration (FDA) for adolescents aged 16-17 years and under FDA emergency use authorization for those aged 12-15 years. In a prospective cohort in Arizona, 243 adolescents aged 12-17 years were tested for SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) each week, irrespective of symptoms, and upon onset of COVID-19-like illness during July 25-December 4, 2021; the SARS-CoV-2 B.1.617.2 (Delta) variant was the predominant strain during this study period. During the study, 190 adolescents contributed fully vaccinated person-time (≥14 days after receiving 2 doses of Pfizer-BioNTech vaccine), 30 contributed partially vaccinated person-time (receipt of 1 dose or receipt of 2 doses but with the second dose completed <14 days earlier), and 66 contributed unvaccinated person-time. Using the Cox proportional-hazards model, the estimated VE of full Pfizer-BioNTech vaccination for preventing SARS-CoV-2 infection was 92% (95% CI = 79%-97%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local virus circulation. These findings from a real-world setting indicate that 2 doses of Pfizer-BioNTech vaccine are highly effective in preventing SARS-CoV-2 infection among Arizona adolescents. CDC recommends COVID-19 vaccination for all eligible persons in the United States, including persons aged 12-17 years.